Immunovant, Inc. (IMVT) is highlighted as one of the best oversold NASDAQ stocks to buy now. Goldman Sachs analyst Corinne Johnson resumed coverage of IMVT with a Hold rating and a price target of $18.00. The company has $714 million in cash and cash equivalents as of March 31, providing runway for announced indications through 2027. IMVT develops treatments for autoimmune diseases with products like batoclimab and IMVT-1402 targeting the FcRn receptor. While IMVT shows potential, other AI stocks may offer greater upside potential and less downside risk. No promotional content included in the article.

Read more at Yahoo Finance: Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating